Header cover image

Hong Kong (HSI) Pharma Industry Analysis

UpdatedFeb 17, 2025
DataAggregated Company Financials
Companies39
  • 7D1.9%
  • 3M-0.8%
  • 1Y2.0%
  • YTDn/a

The Pharma industry is up 1.9% in the last week, with Sino Biopharmaceutical up 8.8%. The industry has been flat over the past 12 months despite the gain this week. Earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the Hong Kong Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 17 Feb 2025HK$430.0bHK$463.6bHK$32.0b8.6x13.5x0.9x
Wed, 15 Jan 2025HK$402.8bHK$458.9bHK$31.7b8x12.7x0.9x
Fri, 13 Dec 2024HK$449.4bHK$462.5bHK$31.9b8.5x14.1x1x
Sun, 10 Nov 2024HK$445.9bHK$467.8bHK$32.4b8.5x13.7x1x
Tue, 08 Oct 2024HK$544.6bHK$477.2bHK$33.1b10.1x16.4x1.1x
Thu, 05 Sep 2024HK$437.5bHK$472.8bHK$32.8b7.8x13.3x0.9x
Sat, 03 Aug 2024HK$418.9bHK$461.8bHK$32.8b7.4x12.8x0.9x
Mon, 01 Jul 2024HK$438.9bHK$461.3bHK$33.7b8.2x13x1x
Wed, 29 May 2024HK$469.8bHK$463.7bHK$33.9b8.6x13.9x1x
Fri, 26 Apr 2024HK$452.4bHK$464.0bHK$33.8b7.5x13.4x1x
Sun, 24 Mar 2024HK$460.5bHK$469.9bHK$32.8b7.8x14x1x
Tue, 20 Feb 2024HK$429.0bHK$470.8bHK$33.6b7.4x12.8x0.9x
Thu, 18 Jan 2024HK$427.5bHK$471.5bHK$33.6b7.2x12.7x0.9x
Sat, 16 Dec 2023HK$489.8bHK$473.3bHK$33.9b8x14.4x1x
Mon, 13 Nov 2023HK$487.0bHK$469.2bHK$31.9b7x15.3x1x
Wed, 11 Oct 2023HK$426.5bHK$469.4bHK$31.6b6.7x13.5x0.9x
Fri, 08 Sep 2023HK$421.1bHK$469.1bHK$31.5b6.7x13.4x0.9x
Sun, 06 Aug 2023HK$471.8bHK$446.7bHK$27.9b9x16.9x1.1x
Tue, 04 Jul 2023HK$492.8bHK$445.5bHK$27.7b9.7x17.8x1.1x
Thu, 01 Jun 2023HK$506.3bHK$448.7bHK$27.9b8.6x18.1x1.1x
Sat, 29 Apr 2023HK$570.2bHK$453.7bHK$28.8b9x19.8x1.3x
Mon, 27 Mar 2023HK$543.3bHK$444.4bHK$33.9b8.7x16x1.2x
Wed, 22 Feb 2023HK$609.1bHK$445.2bHK$35.3b11.3x17.3x1.4x
Fri, 20 Jan 2023HK$628.4bHK$447.3bHK$35.6b10.5x17.7x1.4x
Sun, 18 Dec 2022HK$617.3bHK$441.6bHK$34.7b10.6x17.8x1.4x
Tue, 15 Nov 2022HK$615.1bHK$438.2bHK$34.1b9.5x18x1.4x
Thu, 13 Oct 2022HK$513.9bHK$514.3bHK$39.0b7.7x13.2x1x
Sat, 10 Sep 2022HK$549.0bHK$519.8bHK$40.8b9.7x13.5x1.1x
Mon, 08 Aug 2022HK$595.4bHK$512.4bHK$51.8b7.6x11.5x1.2x
Wed, 06 Jul 2022HK$649.0bHK$514.6bHK$52.2b9.4x12.4x1.3x
Fri, 03 Jun 2022HK$586.3bHK$515.5bHK$52.1b9x11.3x1.1x
Sun, 01 May 2022HK$580.6bHK$516.4bHK$51.8b8.5x11.2x1.1x
Tue, 29 Mar 2022HK$646.9bHK$510.1bHK$48.8b11.5x13.3x1.3x
Thu, 24 Feb 2022HK$691.3bHK$499.3bHK$44.1b9.8x15.7x1.4x
Price to Earnings Ratio

15.7x


Total Market Cap: HK$691.3bTotal Earnings: HK$44.1bTotal Revenue: HK$499.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Pharma Industry Price to Earnings3Y Average 14.5x202320242025
Current Industry PE
  • Investors are relatively neutral on the Hong Kong Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 14.5x.
  • The 3-year average PS ratio of 1.1x is higher than the industry's current PS ratio of 0.93x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 10% per year over the last three years,
  • Revenues have also declined 2.4% per year.
  • This means overall sales from these companies are declining and profits are subsequently falling as well.

Industry Comparison

How does Hong Kong Pharma compare with similar industries?

HK Market4.28%
Healthcare3.72%
Pharma1.92%
Pharma1.92%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
1177 Sino BiopharmaceuticalHK$3.319.6%
+HK$5.3b
6.8%PE26.2x
1093 CSPC Pharmaceutical GroupHK$4.752.6%
+HK$1.4b
-22.3%PE9.9x
512 Grand Pharmaceutical GroupHK$4.644.3%
+HK$665.3m
31.8%PE6.7x
3320 China Resources Pharmaceutical GroupHK$5.431.7%
+HK$565.4m
6.1%PE8.4x
867 China Medical System HoldingsHK$7.783.0%
+HK$555.8m
-34.2%PE12.6x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6996

HK$1.31

Antengene

7D

61.7%

1Y

12.0%

1093

HK$4.75

CSPC Pharmaceutical Group

7D

2.6%

1Y

-22.3%

3692

HK$17.80

Hansoh Pharmaceutical Group

7D

-4.9%

1Y

34.6%

1177

HK$3.31

Sino Biopharmaceutical

7D

9.6%

1Y

6.8%

3933

HK$12.34

United Laboratories International Holdings

7D

-6.2%

1Y

58.4%

867

HK$7.78

China Medical System Holdings

7D

3.0%

1Y

-34.2%

2633

HK$1.25

Jacobson Pharma

7D

-6.0%

1Y

104.9%

3737

HK$0.95

Zhongzhi Pharmaceutical Holdings

7D

-5.0%

1Y

-28.6%

2005

HK$3.22

SSY Group

7D

-2.1%

1Y

-23.5%

2096

HK$7.02

Simcere Pharmaceutical Group

7D

1.6%

1Y

30.2%

6622

HK$1.86

Zhaoke Ophthalmology

7D

35.8%

1Y

9.4%

512

HK$4.64

Grand Pharmaceutical Group

7D

4.3%

1Y

31.8%

1666

HK$4.80

Tong Ren Tang Technologies

7D

-4.2%

1Y

-9.4%